Telix Resubmits FDA Application For Pixclara, Aiming To Improve Glioma Diagnosis For Adults And Children

Telix has announced that it has formally resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for TLX101-Px, also known as Pixclara, Floretyrosine F 18 or 18F-FET. This product is an investigational PET imaging agent developed to help clinicians distinguish between recurrent or progressive glioma and changes caused by previous treatments. It is intended for use in both adult and pediatric patients facing this challenging form of brain cancer.

The resubmission includes all of the additional data and statistical analyses requested by the FDA. Telix noted that its recent Type A meeting with the agency, along with ongoing communication, provided useful clarity on what was needed. The company believes that the strengthened data package, combined with the information already provided in the original NDA, fully responds to the concerns outlined in the FDA’s earlier Complete Response Letter.

TLX101-Px has already received both Orphan Drug and Fast Track designations, reflecting its potential to address a significant unmet medical need. Although 18F-FET PET imaging is widely recognized in international clinical guidelines for its value in evaluating gliomas, there is currently no FDA-approved targeted amino acid PET imaging agent available in the United States for either adult or pediatric brain cancer patients. This has created a notable gap in diagnostic options, especially for those who require clearer insights after undergoing treatment.

Dr. David N. Cade, Telix’s Group Chief Medical Officer, said that the company appreciates the FDA’s recognition of how important it is to improve diagnostic tools for glioma, particularly for patients who have already received therapy. He explained that the updated submission is supported by a strong and comprehensive data set, which is especially significant given the rarity of the condition. He also expressed gratitude to global clinical collaborators for their commitment to advancing access to improved imaging options for patients in the U.S.

Maggie Haynes, Executive Director of the Head for the Cure Foundation, said the brain cancer community is encouraged by the FDA’s consistent engagement and guidance throughout the process. She also noted the agency’s support for the Expanded Access Program for TLX101-Px, which provides eligible patients with early access to the investigational imaging agent. She shared hope that the review will move forward efficiently so that this established and valuable imaging option can reach those who urgently need better diagnostic clarity.